A 62-year-old Chinese man was admitted with central, nonradiating chest pain associated with breathlessness and palpitation, which lasted 10 minutes while at rest.
ECG I NTE R PR E TATIO N
ECG shows a 1-mm ST segment depression in the inferolateral leads, i.e. II, III, aVF, V5-6, with T wave inversion in leads I and aVL ( Fig. 1) . 
CLINICAL COURSE
Cardiac
CA S E 2 CLI N I CA L PR E S E NTATIO N
A 65-year-old man, who was a former chronic smoker and social drinker, was admitted with acute onset of breathlessness associated with wheezing and diaphoresis, without chest pain or palpitations. He denied any history of fever or cough, and had a longstanding history of diabetes mellitus, hypertension, dyslipidaemia, chronic obstructive pulmonary disease and microcytic hypochromic anaemia. The patient had tried nebulisation at home without relief. When the patient first presented to the emergency department, he was feeling drowsy and gasping for breath, and needed to be intubated.
In the intensive care unit, the patient's heart rate was 92 bpm and his BP was 103/67 mmHg. Cardiovascular examination revealed dual heart sounds with a soft, nonradiating ejection systolic murmur at the aortic area. Respiratory examination revealed extensive bilateral wheezes with crepitation and reduced air entry at the lung bases. Post intubation, chest radiograph showed diffuse air space and interstitial opacities in both lungs, with upper lobe diversion and evidence of cardiomegaly (Fig. 3) . The findings were suggestive of acute pulmonary oedema. Describe the ECG in Fig. 4 .
ECG I NTE R PR E TATIO N
ECG showed sinus rhythm, normal axis and deep T wave inversion in leads V2-V6, and prolonged QTc interval (491 msec).
CLINICAL COURSE
Soon after the patient was intubated and admitted to the cardiac intensive care unit, arterial blood gas analysis showed hypoxia with severe respiratory acidosis (pH 7.0, pCO2 118.5 mmHg with 
D I SCU S S IO N
Diabetes mellitus is among the most common chronic diseases in the world, affecting an estimated 180 million people in 2008. (1) It is one of the major risk factors for atherosclerotic vascular disease, including coronary artery disease (CAD). The estimated prevalence of diabetes mellitus among adults in the United States ranges from 4.4% to 17.9%. The disease is associated with a number of micro-and macrovascular complications, including myocardial infarction, stroke, end-stage renal disease, retinopathy and foot ulcers. (2) The National Cholesterol Education Program report from the 
Almost half of all myocardial infarctions are clinically silent or unrecognised, and one-third present with symptoms other than chest discomfort. (9) Silent ischaemia, which is the presence of objective evidence of myocardial ischaemia in the absence of chest discomfort or angina equivalent, is also commonly seen in the diabetic population, with a prevalence of 10%-20%
vs. 1%-4% in the general population. 
The characteristic ECG abnormalities of NSTEMI are 
Implications of ECG changes
In patients with NSTEMI, ST-segment depression portends a worse prognosis than those without, and this is dependent on the severity and extent of ECG changes. (15) The number of leads showing ST depression and the magnitude of ST depression indicates the extent and severity of ischaemia, and correlates with the prognosis. (15) Some studies have cast doubt on the prognostic value of isolated T wave inversion. However, deep symmetrical inversion of the T waves in the anterior chest leads is often related to significant stenosis of the pLAD coronary artery or main stem.
Other features such as an elevation (> 0.1 mV) in lead aVR have been associated with a high probability of left main or triple-vessel CAD and a worse clinical prognosis. 
The TIMI risk score tool, consisting of seven 1-point risk indicators rated on presentation, has been developed and validated for UA/NSTEMI patients, (16, 17) and is useful for the prediction of both 30-day and one-year mortality. A second model is based on the PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using
Integrilin Therapy) trial. (18) Risk models based on the GRACE database have also been developed and validated for in-hospital and six-month outcomes. (19) Therefore, in patients with UA/NSTEMI with high-risk scores, there is increased benefit from more aggressive therapies such as heparin, LMWH, (20, 22) platelet glycoprotein IIb/IIIa inhibition, (22) and an invasive strategy. CAD. (25) In spite of the recent advances in medical technologies and newer stents, revascularisation in diabetic patients with CAD continues to be challenging. (25) Current evidence suggests that revascularisation needs to be personalised based on multiple factors, such as type and severity of coronary artery involvement, myocardial viability, patient preference, financial concerns, comorbidities and the general condition of the patient.
Our second case was a longstanding diabetic patient who presented with acute pulmonary oedema that required invasive ventilation, secondary to non-ischaemic cardiomyopathy. In the absence of significant CAD, it was likely a manifestation of diabetic cardiomyopathy.
As compared to nondiabetic individuals, patients with diabetes mellitus have a two-to five-fold increased risk of heart failure and worse outcomes once heart failure has developed. (26) This increased risk of heart failure observed in diabetic patients is multifactorial and may be a result of ischaemic, metabolic and functional myocardial perturbations. (27) The term 'diabetic cardiomyopathy' was first coined in the early 1970s by Rubler, who identified four patients with diabetic nephrosclerosis and nonischaemic cardiomyopathy during an autopsy. (28) Diabetic cardiomyopathy has since been defined as ventricular dysfunction (both systolic and diastolic) that occurs in diabetic patients, and is independent of other causes such as CAD, hypertension and valvular heart disease. LVH is commonly observed even in the absence of hypertension. (29, 30) 
Pathogenesis of diabetic cardiomyopathy
Pathologic abnormalities that have been identified in the diabetic heart include myocardial lipid overload, altered substrate use, oxidative stress, fibrosis, inflammation and mitochondrial dysfunction. Although significant progress has been made in the understanding of the disease, the precise cause of diabetic cardiomyopathy remains controversial. (31) Some of the pathogenic factors implicated are glucotoxicity (leading to increased formation of advanced glycated end products, causing oxidative stress), lipotoxicity (causing myocardial cell steatosis, fibrosis, impaired calcium handling, abnormal protein C kinase signalling, and increased apoptosis) and inflammation (leading to myocardial cell fibrosis and death or irreversible damage). (30, 31) 
Management of diabetic cardiomyopathy
Although tighter glycaemic control is associated with a lower risk of heart failure, a causal relationship between glycaemic control and heart failure has not been established. The treatment of heart failure in diabetic patients remains similar to that in nondiabetic patients. Evidence from a meta-analysis of beta blocker trials in heart failure, which included 1,883 diabetic and 7,042 nondiabetic subjects, showed that the survival benefit with beta blocker therapy was significant for both groups, with no significant difference between the two groups. (34) The SOLVD (Studies of Left Ventricular Dysfunction) and SAVE (Survival and Ventricular Enlargement) trials have shown that both diabetic and nondiabetic patients benefit equally from ACE inhibitors. (34) (35) (36) In a meta-analysis of ACE inhibitor trials in heart failure, comprising 2,398 diabetics and 10,188 nondiabetics, the survival benefit with ACE inhibitor therapy was found to be similar for those with and without diabetes mellitus. (34) Hence, the mainstay of heart failure treatment for diabetic patients remains the same as that for nondiabetics.
Treatment includes medical management with anti-failure measures, beta blockers, ACE inhibitors/angiotensin II receptor blockers, spironolactone, and in selected cases, device therapy with cardiac resynchronisation. Left ventricular assist devices and heart transplant may be indicated in advanced cases.
ABSTRACT Diabetes mellitus is responsible for diverse cardiovascular complications such as accelerated atherosclerosis, increased plaque burden and diffuse coronar y lesions. It is also a major risk factor for myocardial infarction, stroke and peripheral vascular disease. Here, we present two cases. The first patient had subtle changes in the ECGs, with severe coronary ar ter y disease requiring coronar y ar ter y bypass grafting, while the second had deep T wave inversion in the ECG and was found to have normal coronar y arteries and nonischaemic cardiomyopathy. Although ECG failed to show the severity of the disease, it is invaluable as a simple, noninvasive test to aid in diagnosis. Our two cases stress the importance of a high index of suspicion and the low threshold for investigations in the diabetic population. 
